Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
| ▸ | PER2 | O15055 | 1/20 | 0.32 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.32 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL75553 | 0.78 | POLB (0.39) | POLBGRIA4PER2CRY1CRY2 | |
| SCHEMBL22063184 | 0.74 | POLB (0.37) | POLBGRIA4PER2CRY1CRY2 | |
| SCHEMBL15677643 | 0.74 | CA2 (0.46) | POLBGRIA4PER2CRY1CRY2 | |
| SCHEMBL14930638 | 0.74 | POLB (0.37) | POLBGRIA4PER2CRY1CRY2 | |
| SCHEMBL15491574 | 0.74 | PER2 (0.38) | POLBGRIA4PER2CRY1CRY2 | |
| SCHEMBL2061461 | 0.74 | POLB (0.37) | POLBGRIA4PER2CRY1CRY2 | |
| SCHEMBL7627757 | 0.74 | POLB (0.37) | POLBGRIA4PER2CRY1CRY2 | |
| SCHEMBL5020907 | 0.72 | ALDH1A1 (0.39) | POLBGRIA4PER2CRY1CRY2 | |
| SCHEMBL2835677 | 0.70 | POLB (0.34) | POLBPER2CRY1CRY2CA2 | |
| SCHEMBL19074536 | 0.70 | GRIA4 (0.35) | POLBGRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044160-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | POLB 3278/4885GRIA4 3510/4885PER2 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.